DK1171111T3 - Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning - Google Patents

Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning

Info

Publication number
DK1171111T3
DK1171111T3 DK00917258T DK00917258T DK1171111T3 DK 1171111 T3 DK1171111 T3 DK 1171111T3 DK 00917258 T DK00917258 T DK 00917258T DK 00917258 T DK00917258 T DK 00917258T DK 1171111 T3 DK1171111 T3 DK 1171111T3
Authority
DK
Denmark
Prior art keywords
carnitine
high content
tablets
granules
alkanoyl
Prior art date
Application number
DK00917258T
Other languages
Danish (da)
English (en)
Inventor
Ken Hassen
Original Assignee
Biosint S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosint S P A filed Critical Biosint S P A
Application granted granted Critical
Publication of DK1171111T3 publication Critical patent/DK1171111T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
DK00917258T 1999-03-26 2000-03-22 Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning DK1171111T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000189A IT1305308B1 (it) 1999-03-26 1999-03-26 Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione
PCT/IT2000/000097 WO2000057873A2 (en) 1999-03-26 2000-03-22 Granulate with high content of l-carnitine or an alkanoyl l-carnitine

Publications (1)

Publication Number Publication Date
DK1171111T3 true DK1171111T3 (da) 2003-08-25

Family

ID=11406608

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00917258T DK1171111T3 (da) 1999-03-26 2000-03-22 Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning

Country Status (20)

Country Link
US (1) US6485741B2 (de)
EP (1) EP1171111B1 (de)
JP (2) JP4637367B2 (de)
KR (1) KR100729848B1 (de)
CN (1) CN1158072C (de)
AT (1) ATE238784T1 (de)
AU (1) AU780413B2 (de)
CA (1) CA2363038C (de)
CZ (1) CZ301266B6 (de)
DE (1) DE60002454T2 (de)
DK (1) DK1171111T3 (de)
ES (1) ES2197867T3 (de)
HU (1) HU228588B1 (de)
IL (2) IL144957A0 (de)
IT (1) IT1305308B1 (de)
PL (1) PL207961B1 (de)
PT (1) PT1171111E (de)
SK (1) SK285565B6 (de)
TR (1) TR200102802T2 (de)
WO (1) WO2000057873A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1047889B (en) * 1999-09-03 2009-04-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same
CN1686089B (zh) * 2005-05-08 2010-08-18 北京健健康康生物技术有限公司 一种可直接压片的木糖醇颗粒及其制备方法
CN101912045B (zh) * 2005-07-05 2013-07-31 隆萨股份公司 生产干肉碱粉末或颗粒的喷雾干燥法
MX342962B (es) * 2009-09-18 2016-06-07 Teva Pharmaceuticals Holdings Mexico S A De C V Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.
EP2335495A1 (de) 2009-12-11 2011-06-22 Lonza Ltd. Carnitin-Granulat und Verfahren zu dessen Herstellung
CN102349881B (zh) * 2011-10-26 2013-06-26 东北制药（沈阳）科技发展有限公司 一种左卡尼汀薄膜衣片及其制备方法
CN105695398A (zh) * 2016-04-25 2016-06-22 广西大学 含o-乙酰基-l-肉碱盐酸盐的水牛卵母细胞体外成熟液及培养方法
JP7366612B2 (ja) * 2019-07-09 2023-10-23 東和薬品株式会社 レボカルニチンを含有する錠剤
KR20230011999A (ko) 2020-05-15 2023-01-25 알파시그마 에스.피.에이. 메틸폴레이트를 포함하는 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2921852A1 (de) * 1979-05-29 1980-12-11 Fresenius Chem Pharm Ind Lipide senkendes mittel
IT1119853B (it) * 1979-09-21 1986-03-10 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente l-carnitina per il trattamento delle dislipidemie ed iperlipo proteinemie
JPS59222412A (ja) * 1983-06-01 1984-12-14 Earth Chem Corp Ltd 心臓疾患治療薬
DE3463261D1 (en) * 1983-12-28 1987-05-27 Sigma Tau Ind Farmaceuti Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1190370B (it) * 1985-06-19 1988-02-16 Zambon Spa Composizione farmaceutica solida per uso orale
JPH03120211A (ja) * 1989-10-04 1991-05-22 Earth Chem Corp Ltd 粒状カルニチン製剤
US5073376A (en) * 1989-12-22 1991-12-17 Lonza Ltd. Preparations containing l-carnitine
JPH0656659A (ja) * 1992-06-10 1994-03-01 Natl Sci Council 直接打錠できる薬学組成物及びその錠剤の製造法
EP0681839A3 (de) * 1994-05-12 1997-11-12 Hirohiko Kuratsune Acylcarnitin-enthaltende pharmazeutische Zusammensetzung
JPH0812569A (ja) * 1994-06-24 1996-01-16 Takeda Chem Ind Ltd 塩化カルニチン吸着固形物
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
JP3120211B2 (ja) 1996-05-14 2000-12-25 スガツネ工業株式会社 オーバーヘッドドア開閉用ダンパー
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
IT1291126B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine
IT1291133B1 (it) * 1997-04-07 1998-12-29 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio tartrato
IT1290600B1 (it) * 1997-04-30 1998-12-10 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato

Also Published As

Publication number Publication date
DE60002454D1 (de) 2003-06-05
TR200102802T2 (tr) 2002-04-22
PT1171111E (pt) 2003-09-30
CN1158072C (zh) 2004-07-21
JP2002540153A (ja) 2002-11-26
AU780413B2 (en) 2005-03-17
HUP0200465A2 (en) 2002-06-29
US20020025984A1 (en) 2002-02-28
CA2363038C (en) 2008-10-14
JP2001097353A (ja) 2001-04-10
WO2000057873A3 (en) 2001-04-19
EP1171111B1 (de) 2003-05-02
ES2197867T3 (es) 2004-01-16
KR20010114227A (ko) 2001-12-31
JP4637367B2 (ja) 2011-02-23
PL207961B1 (pl) 2011-02-28
HU228588B1 (en) 2013-04-29
DE60002454T2 (de) 2004-03-18
ITRM990189A1 (it) 2000-09-26
PL350908A1 (en) 2003-02-10
ATE238784T1 (de) 2003-05-15
CZ301266B6 (cs) 2009-12-23
CN1345235A (zh) 2002-04-17
IL144957A (en) 2006-08-01
US6485741B2 (en) 2002-11-26
KR100729848B1 (ko) 2007-06-19
SK11592001A3 (sk) 2001-12-03
AU3834400A (en) 2000-10-16
CA2363038A1 (en) 2000-10-05
EP1171111A2 (de) 2002-01-16
IL144957A0 (en) 2002-06-30
IT1305308B1 (it) 2001-05-04
CZ20013078A3 (cs) 2002-02-13
WO2000057873A2 (en) 2000-10-05
SK285565B6 (sk) 2007-03-01

Similar Documents

Publication Publication Date Title
CA2199778A1 (en) Extended release formulation of venlafaxine
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO1998004249A3 (de) Tramadol multiple unit formulierungen
HK1047537A1 (zh) 多元藥物劑型
FI944035L (fi) Tramadolisuolaa sisältävä lääkeaine, jolla on viivästynyt vaikuttavan aineen vapautuminen
AU2003286994A1 (en) Modified release pharmaceutical composition
AU8009998A (en) Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
NO880904L (no) Farmasoeytisk tablett, farmasoeytisk granulat og fremgangsmaate for deres fremstilling.
NO841518L (no) Delbare tabletter med forsinket frigjoering av virkestoff, og fremgangsmaate for fremstilling derav
DE60124294D1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
WO1999022724A3 (en) Extended release formulation containing venlafaxin
DK1171111T3 (da) Granulat, som har højt indhold af L-carnitin eller et alkanoyl L-carnitin, og som er særlig egnet til fremstilling af tabletter ved direkte presning
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
DK616186A (da) Farmaceutisk praeparat med retarderet frigivelse af ibuprofen
AU4519399A (en) Anti-inflammatory pharmaceutical formulations
FI945313L (fi) Parannetun biokäytettävyyden omaavat tabletit, jotka sisältävät dikloorimetyleenifosfonihappoa vaikuttavana aineena
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
DK0755919T3 (da) Substituerede kanelsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som hjerte-kredsløbs-medikament e
GB2295966B (en) Direct compression tablets
ES2189739T3 (es) Composiciones de betahistina de liberacion controlada.
WO1999018941A3 (en) Ih-MODULATORS
AU5139596A (en) Pharmaceutical matrix pellets, tablets and composition for the preparation thereof
CA2473718A1 (en) Immediate-release pharmaceutical dosage form comprising polymorphous tibolone
AU2001274000A1 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
IE820810L (en) Pharmaceutical preparations for treatment of diabetes